Patents Examined by D Margaret M Seaman
  • SARS-CoV-2 inhibitors for treating coronavirus infections
    Patent number: 11731944
    Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for treating a SARS-CoV-2 infection.
    Type: Grant
    Filed: February 8, 2023
    Date of Patent: August 22, 2023
    Assignee: Insilico Medicine IP Limited
    Inventors: Xiao Ding, Jingjing Peng, Feng Ren, Xiaoyu Ding, Bogdan Zagribelnyy, Yan A. Ivanenkov
  • Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
    Patent number: 11690830
    Abstract: A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: July 4, 2023
    Assignee: IntraBio Ltd.
    Inventor: Michael Strupp
  • Compounds for treating diseases associated with a mitochondrial dysfunction
    Patent number: 11684611
    Abstract: The present invention relates to a compound of the following formula (A): or a pharmaceutically acceptable salt or hydrate thereof, for use in the prevention or treatment of a disease associated with a mitochondrial dysfunction.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: June 27, 2023
    Assignee: Amabiotics
    Inventors: Antoine Danchin, Agnieszka Sekowska, Patrice Garnier
  • Highly purified batches of pharmaceutical grade 1-deoxygalactonojirimycin compounds
    Patent number: 11685718
    Abstract: Provided are methods of producing Active Pharmaceutical Ingredient (API) grade migalastat hydrochloride, and for purifying intermediate grade migalastat hydrochloride. Further provided are methods of producing [(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol hydrochloride (lucerastat hydrochloride) and other 1-deoxygalactonojirimycin compounds, as well as methods of purifying intermediate grade lucerastat hydrochloride and other 1-deoxygalactonojirimycin compounds.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: June 27, 2023
    Assignee: Amicus Therapeutics, inc.
    Inventors: Kamlesh Sheth, Sergey Tesler, James Cartwright, Clive King, Wendy Cross
  • 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease
    Patent number: 11680062
    Abstract: Disclosed are 3,4-methylenedioxyphenylimidazolylethanonexime ether derivatives, a preparation method and use thereof, and a drug for the treatment of Alzheimer's disease, which relates to the technical field of preparation of acetophenone oxime ether compounds. The (Z)-3,4-methylenedioxyphenylimidazolylethanonexime ether derivatives provided by the present disclosure show a significant effect on the inhibition of NO production, with an EC50 of 2.07-5.41 ?mol/L. Compared with the positive control group of quercetin (with an EC50 of 9.56 ?mol/L) and oxiconazole (with an EC50 of 13.5 ?mol/L), the inhibitory effect is stronger without significant cytotoxicity (cell viability >90%), which can be used to prepare drugs for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: June 20, 2023
    Assignee: NORTHWEST A & F UNIVERSITY
    Inventors: Jiangjiang Tang, Zhaoyuan Bian, Lanfang Huang, Bo Ren, Ping Xiang, Jinming Gao
  • Pyridone amides as modulators of sodium channels
    Patent number: 11673864
    Abstract: The invention relates to pyridone amide compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: June 13, 2023
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Sara Sabina Hadida Ruah, Corey Anderson, Vijayalaksmi Arumugam, Iuliana Luci Asgian, Brian Richard Bear, Andreas P. Termin, James Philip Johnson
  • Treatment of HER2 positive cancers
    Patent number: 11666572
    Abstract: In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: June 6, 2023
    Assignee: Seagen Inc.
    Inventors: Scott Peterson, Luke Walker
  • Use of quinoline derivatives for the treatment of inflammatory diseases
    Patent number: 11649210
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: May 16, 2023
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Didier Scherrer, Jamal Tazi, Florence Mahuteau, Romain Najman
  • Use of quinoline derivatives for the treatment of inflammatory diseases
    Patent number: 11649211
    Abstract: The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(?O)—(OR3)(OR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among:
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: May 16, 2023
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Romain Najman, Florence Mahuteau, Didier Scherrer, Karim Chebli, Michael Hahne
  • Selective androgen receptor degrader (SARD) ligands and methods of use
    Patent number: 11648234
    Abstract: This invention is directed to selective androgen receptor degrader (SARD) compounds pharmaceutical compositions and uses thereof in treating early prostate cancer, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: May 16, 2023
    Assignee: University of Tennessee Research Foundation
    Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He
  • Therapeutic agent for mental retardation or autism
    Patent number: 11642337
    Abstract: A novel therapeutic agent effective for the treatment of intellectual disability or autism is disclosed. The therapeutic agent for intellectual disability or autism contains, as an active component(s), at least one selected from the group consisting of tipifarnib and lonafarnib. Examples of the intellectual disability include memory impairment. Examples of the memory impairment include memory impairment caused by abnormality of the Tsc1 gene and/or Tsc2 gene, and epilepsy-induced memory impairment. Also provided is a method of treating intellectual disability or autism, comprising administering an effective amount of at least one selected from the group consisting of tipifarnib and lonafarnib to a patient with intellectual disability or autism.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: May 9, 2023
    Assignee: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
    Inventors: Kanato Yamagata, Tadayuki Shimada, Hiroko Sugiura, Shin Yasuda
  • Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
    Patent number: 11639335
    Abstract: The invention provides novel asymmetric and symmetric bisaminoquinolmes and related compounds, methods of treatment and syntheses. The novel compounds exhibit effective anticancer activity and are useful in the treatment of a variety of autophagy-related disorders.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: May 2, 2023
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Ravi K. Amaravadi, Jeffrey D. Winkler
  • Selective estrogen receptor degraders
    Patent number: 11634426
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: April 25, 2023
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall, Jennifer Anne McMahon
  • Small molecule inhibitors of Ebola and Lassa fever viruses and methods of use
    Patent number: 11629139
    Abstract: Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: April 18, 2023
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.
    Inventors: James Morgan Cunningham, Hu Liu, Ye Tian, Katie Kyungae Lee
  • Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
    Patent number: 11623916
    Abstract: Provided are methods of producing a batch of 1,2,3,6-tetrapivaloyl-D-galactofuranoside; 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-D-galactofuranoside; intermediate grade migalastat hydrochloride; and/or migalastat hydrochloride. Also provided are methods of determining the purity of a batch of 1,2,3,6-tetrapivaloyl-D-galactofuranoside; 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-D-galactofuranoside; intermediate grade migalastat hydrochloride; and/or migalastat hydrochloride. Also provided are methods of distributing a batch of 1,2,3,6-tetrapivaloyl-D-galactofuranoside; 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-D-galactofuranoside; intermediate grade migalastat hydrochloride; and/or migalastat hydrochloride. Also provided are methods of assessing suitability of migalastat hydrochloride for medical use.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: April 11, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Kamlesh Sheth, Sergey Tesier, James Cartwright, Clive King, Wendy Cross
  • Dual mechanism inhibitors for the treatment of disease
    Patent number: 11618748
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: April 4, 2023
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Bicyclic amide compounds and methods of use thereof
    Patent number: 11607396
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, R2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: March 21, 2023
    Assignee: Genentech, Inc.
    Inventors: Snahel Patel, Gregory Hamilton, Guiling Zhao, Huifen Chen
  • Crystalline form of LNP023
    Patent number: 11603363
    Abstract: Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: March 14, 2023
    Assignee: Novartis AG
    Inventors: Zichen Jia, Philipp Lustenberger, Marie Meyer, Massimo Moratto
  • Compound for use against pathogenic and species and
    Patent number: 11596626
    Abstract: The present invention relates to a compound, which can be used in the prevention and treatment of infections with pathogenic Neisseria species, in particular N. gonorrhoeae and N. meningitidis (the gonococcus and the meningococcus, respectively), and other pathogenic bacteria (e.g. Haemophilus species or Moraxella catarrhalis), and which can be used for disinfecting a substrate from said bacteria. Moreover, the present invention relates to a corresponding pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: March 7, 2023
    Assignee: Universität Konstanz
    Inventors: Thomas Böttcher, David Szamosvari, Christof Hauck, Tamara Schuhmacher, Petra Muenzner-Voight
  • Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
    Patent number: 11590111
    Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: February 28, 2023
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Ivan Viktorovich Efremov, Steven Kazmirski, Qingyi Li, Lorin A. Thompson, III, Owen Brendan Wallace, Shawn Donald Johnstone, Feng Zhou, Peter Rahl